| Literature DB >> 26083891 |
Pollyanna Barros Batista1, Eny Maria Goloni Bertollo2, Danielle de Souza Costa1, Lucas Eliam3, Karin Soares Gonçalves Cunha4, José Renan Cunha-Melo1, Luiz Guilherme Darrigo Junior5, Mauro Geller6, Ingrid Faria Gianordoli-Nascimento1, Luciana Gonçalves Madeira1, Hérika Martins Mendes1, Débora Marques de Miranda1, Nikolas Andre Mata-Machado7, Eric Grossi Morato1, Érika Cristina Pavarino2, Luciana Baptista Pereira1, Nilton Alves de Rezende1, Luíza de Oliveira Rodrigues1, Jorge Bezerra Cavalcanti Sette1.
Abstract
Part 1 of this guideline addressed the differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH). NF shares some features such as the genetic origin of the neural tumors and cutaneous manifestations, and affects nearly 80 thousand Brazilians. Increasing scientific knowledge on NF has allowed better clinical management and reduced rate of complications and morbidity, resulting in higher quality of life for NF patients. Most medical doctors are able to perform NF diagnosis, but the wide range of clinical manifestations and the inability to predict the onset or severity of new features, consequences, or complications make NF management a real clinical challenge, requiring the support of different specialists for proper treatment and genetic counseling, especially in NF2 and SCH. The present text suggests guidelines for the clinical management of NF, with emphasis on NF1.Entities:
Mesh:
Year: 2015 PMID: 26083891 DOI: 10.1590/0004-282X20150042
Source DB: PubMed Journal: Arq Neuropsiquiatr ISSN: 0004-282X Impact factor: 1.420